BRAF and retinal detachment: The two main side effects of these therapies are uveitis, in the case of B-Raf inhibitors, and for MEK inhibitors, central serous chorioretinopathy [214], a condition characterized by leakage and accumulation of fluid under the retina (usually in the region of the central macula), retinal detachment and visual impairment (often temporary, with blurred or gray spots in the central visual field).